Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.
作者信息
Curcio Daniel
出版信息
J Clin Microbiol. 2008 May;46(5):1892-3. doi: 10.1128/JCM.02494-07.
Abstract
摘要
相似文献
1
Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.
J Clin Microbiol. 2008 May;46(5):1892-3. doi: 10.1128/JCM.02494-07.
2
Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation.
J Antimicrob Chemother. 2010 Jun;65(6):1311-2. doi: 10.1093/jac/dkq116. Epub 2010 Apr 8.
3
EUCAST technical note on tigecycline.
Clin Microbiol Infect. 2006 Nov;12(11):1147-9. doi: 10.1111/j.1469-0691.2006.01578.x.
4
Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
J Clin Microbiol. 2008 Feb;46(2):817-20. doi: 10.1128/JCM.01340-07. Epub 2007 Dec 12.
5
[Tigecycline: 10 years of history and still in full force].
Rev Esp Quimioter. 2015 Apr;28(2):61-78.
6
[Tigecycline: antimicrobial action, chemotherapeutic efficacy and adverse reactions].
Antibiot Khimioter. 2009;54(1-2):63-6.
7
High serum concentrations of cyclosporin related to administration of tigecycline.
Eur J Clin Pharmacol. 2009 Jan;65(1):101-3. doi: 10.1007/s00228-008-0557-8. Epub 2008 Sep 16.
8
Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review.
J Antimicrob Chemother. 2014 Oct;69(10):2606-10. doi: 10.1093/jac/dku189. Epub 2014 May 30.
9
[Tigecycline, the first of a new class of antibiotics: the glycylcyclines].
Rev Esp Quimioter. 2007 Mar;20(1):19-35.
10
Tigecycline: place in therapy and important considerations.
Am J Health Syst Pharm. 2006 Jul 1;63(13):1233. doi: 10.2146/ajhp060206.
引用本文的文献
1
Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models.
Microbiol Spectr. 2024 Jan 11;12(1):e0128923. doi: 10.1128/spectrum.01289-23. Epub 2023 Dec 4.
2
Current and Emerging Treatment Options for Multidrug Resistant Urosepsis: A Review.
Antibiotics (Basel). 2022 Dec 15;11(12):1821. doi: 10.3390/antibiotics11121821.
3
Combined Rifampin and Sulbactam Therapy for Multidrug-Resistant Acinetobacter Baumannii Ventilator-Associated Pneumonia in Pediatric Patients.
J Anesth Perioper Med. 2018 Jul;5(4):176-185. doi: 10.24015/JAPM.2018.0072.
4
Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management.
Infect Drug Resist. 2015 Jul 24;8:217-30. doi: 10.2147/IDR.S54125. eCollection 2015.
5
β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula.
Clin Microbiol Rev. 2013 Jul;26(3):361-80. doi: 10.1128/CMR.00096-12.
6
Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens.
Curr Infect Dis Rep. 2013 Apr;15(2):109-15. doi: 10.1007/s11908-013-0315-7.
7
Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
Antimicrob Agents Chemother. 2012 Nov;56(11):5744-8. doi: 10.1128/AAC.00402-12. Epub 2012 Aug 27.
8
In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Antimicrob Agents Chemother. 2012 Aug;56(8):4516-8. doi: 10.1128/AAC.00234-12. Epub 2012 May 29.
9
Ertapenem-induced reduction in valproate levels: case report and review of the literature.
Can J Hosp Pharm. 2010 Jul;63(4):315-22. doi: 10.4212/cjhp.v63i4.936.
10
Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.
Antimicrob Agents Chemother. 2011 Dec;55(12):5893-9. doi: 10.1128/AAC.00387-11. Epub 2011 Oct 3.
本文引用的文献
1
Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
J Clin Microbiol. 2008 Feb;46(2):817-20. doi: 10.1128/JCM.01340-07. Epub 2007 Dec 12.
2
Rapid development of Acinetobacter baumannii resistance to tigecycline.
Pharmacotherapy. 2007 Aug;27(8):1198-201. doi: 10.1592/phco.27.8.1198.
3
Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.
J Chemother. 2005 Aug;17 Suppl 1:12-22. doi: 10.1179/joc.2005.17.Supplement-1.12.
4
Tigecycline.
J Antimicrob Chemother. 2005 Sep;56(3):470-80. doi: 10.1093/jac/dki248. Epub 2005 Jul 22.
Zotero 插件